ArticleCell proliferation2020
MicroRNA-214-3p modified tetrahedral framework nucleic acids target survivin to induce tumour cell apoptosis.
Article in Cell proliferation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Tetrahedral framework nucleic acids: Nanokeys unlocking a new era of precision biomedicine.Journal of advanced research · 2026Review
- DNA Nanostructures for siRNA Delivery.Bioconjugate chemistry · 2026Review
- Nano MiRNA-Functionating Tetrahedral Framework Nucleic Acid for Cartilage-Targeted Ferritinophagy Modulation to Attenuate Temporomandibular Joint Osteoarthritis.Small science · 2026Article
- Article
- Role of miRNA‑214‑3p in cancer (Review).Oncology reports · 2025Review
- Enzyme-Responsive Nanoparachute for Targeted miRNA Delivery: A Protective Strategy Against Acute Liver and Kidney Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A bioswitchable delivery system for microRNA therapeutics based on a tetrahedral DNA nanostructure.Nature protocols · 2025Review
- Adoption of a Tetrahedral DNA Nanostructure as a Multifunctional Biomaterial for Drug Delivery.ACS pharmacology & translational science · 2024Review
- Advancements in Aptamer-Driven DNA Nanostructures for Precision Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Application and prospects of nucleic acid nanomaterials in tumor therapy.RSC advances · 2023Review
- Screening and identification of miR-181a-5p in oral squamous cell carcinoma and functional verification in vivo and in vitro.BMC cancer · 2023Article
- MicroRNA-656-3p inhibits colorectal cancer cell migration, invasion, and chemo-resistance by targeting sphingosine-1-phosphate phosphatase 1.Bioengineered · 2022Article
- Pharmaceutical applications of framework nucleic acids.Acta pharmaceutica Sinica. B · 2022Review
- A nanobody-based molecular toolkit for ubiquitin-proteasome system explores the main role of survivin subcellular localization.Frontiers in bioengineering and biotechnology · 2022Article
- Tetrahedral DNA nanostructures for effective treatment of cancer: advances and prospects.Journal of nanobiotechnology · 2021Review
- miRNA-214-5p inhibits prostate cancer cell proliferation by targeting SOX4.World journal of surgical oncology · 2021Article
- MicroRNA 320, an Anti-Oncogene Target miRNA for Cancer Therapy.Biomedicines · 2021Review
- FOXM1/lncRNA TYMSOS/miR-214-3p-Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non-Small Cell Lung Carcinoma.Frontiers in molecular biosciences · 2021Article
- Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics.Stem cell reviews and reports · 2020Review
- MicroRNA-214-3p modified tetrahedral framework nucleic acids target survivin to induce tumour cell apoptosis.Cell proliferation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
objectivesDue to the instability of microRNAs, the applications of microRNA are currently limited. Thus, we utilized tetrahedral framework nucleic acids and a targeted microRNAs to form a stable nanocomposite to explore whether this nanocomposite can promote apoptosis of tumour cells. MATERIALS AND
methodsIn our study, the survivin gene, which is expressed only in tumour cells and embryonic cells, was selected as the target gene; miRNA-214-3p, which can reduce the expression of survivin, was modified onto tetrahedral framework nucleic acid, thereby producing a reduction in the expression of survivin upon intracellular delivery and eventually leading to tumour cell apoptosis.
resultsBy comparing the stability of microRNAs with that of microRNA-tetrahedral framework nucleic acid, we proved the superiority of this carrier system. The results of flow cytometry showed that after treated with this complex, the ratio of A549 cells in both late and early period of apoptosis in miRNA-214-3p-tetrahedral framework nucleic acid group had doubled and the cell cycle in the G2-M phase had declined. The decrease in the expression of anti-apoptotic protein and the increase in the expression of pro-apoptotic protein indicate that the ability of this complex to function in cells also makes it attractive as a new targeted therapy for cancer.
conclusionThe unique expression of survivin in tumour cells and embryonic cells makes microRNA-tetrahedral framework nucleic acid a new targeted therapy. In addition, due to the functional diversity of microRNAs, this delivery system approach can be applied to a wide variety of fields, such as targeted therapy and tissue regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.